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Background: Electronic cigarettes (e-cigarettes) are advertised to tobacco users as a tool to decrease cigarette
consumption and to reduce toxic exposure associated with conventional tobacco smoking. Little is known about
the compounds contained in such products, their exposure and long-term health effects.
Methods: NMR spectroscopy was used to ascertain the content of several constituents of e-cigarette liquids
including nicotine, solvents and some bioactive flavour compounds. Risk assessment was based on probabilistic
exposure estimation and comparison with toxicological thresholds using the margin of exposure (MOE) approach.
Results: In 54 samples of e-cigarette liquids, the average nicotine content was 11 mg/ml. Only 18 from 23 samples
were confirmed as nicotine-free samples and in one e-cigarette liquid nicotine was not detected while being
declared on the labelling. Major compounds of e-cigarette liquids include glycerol (average 37 g/100 g), propylene
glycol (average 57 g/100 g) and ethylene glycol (average 10 g/100 g). Furthermore, 1,3-propanediol, thujone and
ethyl vanillin were detected in some samples. The average exposure for daily users was estimated as 0.38 mg/kg
bw/day for nicotine, 8.9 mg/kg bw/day for glycerol, 14.5 mg/kg bw/day for 1,2-propanediol, 2.1 mg/kg bw/day for
ethylene glycol, and below 0.2 mg/kg bw/day for the other compounds. The MOE was below 0.1 for nicotine, but
all other compounds did not reach MOE values below 100 except ethylene glycol and 1,2-propanediol.
Conclusions: NMR spectroscopy is a useful and rapid method to simultaneously detect several ingredients in
e-cigarette liquids. From all compounds tested, only nicotine may reach exposures that fall into a high risk category
with MOE <1. Therefore, e-cigarette liquid products should be subjected to regulatory control to ensure consistent
nicotine delivery. Solvents with more favourable toxicological profiles should be used instead of ethylene glycol
and 1,2-propanediol, which may fall into a risk category with MOE < 100.
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An electronic cigarette (e-cigarette) is a part of an emer-
ging class of electronic nicotine-delivery systems. These
devices aerosolize nicotine (if contained) and produce a
vapour that emulates that of tobacco cigarettes but pur-
portedly has fewer traditional toxins than secondhand
smoke [1]. The awareness about these products and avail-
ability of e-cigarettes on the Internet, including in Web
searches, virtual user communities and online shops has
increased dramatically in recent years [1,2], however, only* Correspondence: Lachenmeier@web.de
†Equal contributors
2Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe,
Weissenburger Strasse 3, 76187 Karlsruhe, Germany
Full list of author information is available at the end of the article
© 2014 Hahn et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.few studies have been dedicated so far to the qualitative
composition and toxicological characterization of these
products [3,4].
The benefits and risks of electronic cigarette use are a
subject of discussion among health organizations and re-
searchers [5]. First, only limited studies have evaluated the
effects of electronic cigarettes on human health. While e-
cigarettes may have negligible influence on blood count
indices, carbon monoxide exposure and heart rate [5-8], it
was found that e-cigarettes may contain additional impu-
rities in the liquids or vapour (e.g., polyaromatic hydrocar-
bons, aldehydes and acrolein), although at much lower
concentrations than the ones found in normal cigarettes
[9,10]. Furthermore, recent research suggests that thesehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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provide unreliable nicotine delivery [1]. Finally, few
and controversial empirical studies exist to determine
whether e-cigarettes have potential as smoking cessa-
tion products [5,9,11].
In general, electronic cigarettes often contain ingredi-
ents such as propylene glycol, glycerol, ethylene glycol
and polyethylene glycol mixed with concentrated flavours,
and optionally, a variable percentage of nicotine [10,12-14].
Besides these major compounds, a number of other organic
substances can be found in liquid formulated products
and/or the vapour phase produced by an e-cigarette unit.
These include tobacco specific nitrosoamines (TSNA) such
as N-nitrosonicotine (NNN), N-nitrosoanabasine (NAB),
N-nitrosoanabatine (NAT) and 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) [10,12,14] or tobacco-
specific impurities such as cotinine, anabasine and
myosmine [12,13]. It was recently shown that e-cigarette
liquids can be adulterated with pharmacologically active
ingredients or their analogues such as rimonabant and
amino-tadalafil [15].
Given the large increase in awareness and use of e-
cigarettes and the unknown impact of their use on
cigarette smoking behaviours and long-term health, de-
velopment of analytical methodologies for these prod-
ucts is required. Previous research involved typically gas
or liquid chromatography, combined with mass spectro-
metric detection for the analysis of such products, how-
ever, only a limited number of samples have been
investigated in each particular study [13,14,16-20]. Con-
sidering high throughput including minimal sample
preparation, fast spectra acquisition and processing, we
hypothesized that direct nuclear magnetic resonance
(NMR) spectroscopy might be applicable for a high
throughput screening of e-cigarette liquids.
Some studies have found very inconsistent nicotine
contents in some products regarding the labelling, i.e., e-
cigarette liquids advertised as containing no nicotine
may contain the substance and, in contrast, some prod-
ucts did not contain nicotine despite its presence being
labelled [13,15]. Therefore, our study was principally
aimed to develop a reliable and simple analytical tool
based on NMR spectroscopy to control the absence/
presence of nicotine in e-cigarette liquids. However, as
the scope of quantitative NMR lies beyond quantifica-
tion of a single analyte in a given matrix [21,22], we ex-
panded our methodology also for the determination of
other major compounds in e-cigarette liquids (solvents
and flavour compounds). The procedure was then ap-
plied to analyse a large sample collection (n = 54) of e-
cigarette liquids that have been bought over the Internet.
Finally, the exposure of the consumer is estimated based
on the analytical results and a toxicological assessment
is provided.Methods
Sampling and chemical analysis
A total of 54 e-cigarette liquid samples was analysed. This
includes e-cigarette liquids (n = 20) submitted to the
CVUA Karlsruhe for official medicines and tobacco con-
trol purposes in Baden-Württemberg, Germany. Further-
more, an internet-based market research was conducted
to identify products offered to German consumers. To do
this, we searched for the German terms “E-Zigaretten
Liquids kaufen”, “E-Liquids Kaufen”, “E-Liquids Flash”,
“E-Liquids Hanf”, “E-Liquids Marihuana” using the web
platforms google.de, amazon.de and ebay.de. We also in-
cluded search terms such as “E-Liquids Cialis”, “E-Liquids
Vitamin“, because the German Federal Institute for Risk
Assessment (BfR) recently found pharmacological active
substances such as tadalafil, caffeine or vitamins in these
products [23]. In total, 13 on-line shops were selected, that
are selling such liquids. Most of the shops (n = 8) were
located in Germany, one was located in Spain, three were
located in the United Kingdom and one was located in
Romania. Based on the invoices, it seems that several
shops, though being located in countries outside Germany,
had local partners, who handled the shipping and retur-
ning of the good, if necessary. The liquids were sent to us
in envelopes or parcels. Most of the products were labelled
as “Liquids for E-Cigarettes” or simply “E-Liquid”, but in
some cases the products did not contain any labelling and
in one case the products were labelled as “Air freshener”.
From the identified on-line shops, we selected samples
using a risk-oriented approach. For example, we preferen-
tially obtained samples where the presence of bioactive
flavour compounds could be assumed. Additionally,
several samples suspected of containing illegal or un-
usual substances were bought, such as products labelled
as “Marihuana-Flavour”, “Mary Jane Flavour”, “Vitamin-
Mix” or “Multi Vitamin”. Furthermore, several samples
with tobacco and beverage flavour (such as cola, wine, en-
ergy drink or absinthe flavour) were included. We tried to
obtain all varieties of e-cigarette liquids regarding declared
nicotine content. We obtained several samples, claimed as
nicotine-free and samples with medium or high nicotine
content (the labelled nicotine content varied between 6
and 54 mg/ml).
NMR analysis of electronic cigarette liquids
The chemical analysis was conducted using NMR spec-
troscopy based on a procedure previously developed for
analysis of alcoholic beverages [24].
All solvents and reagents used were in pro analysis qua-
lity: nicotine, menthol, safrole (Sigma Aldrich, Steinheim,
Germany), propylene glycol, 1,3-butanediol, 1,3-pro-
panediol, ethylene glycol, glycerol, ethyl vanillin, cam-
phor, α-thujone, coumarin, diethyleneglycol (Fluka,
Buchs, Switzerland).
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liquids composition, we decided to apply two separate
sample preparations for each sample. To measure water-
soluble compounds (including nicotine), 60 μL of a sample
was mixed with 480 μL of distilled water and 60 μL of
NMR buffer (pH 7.4; 1.5 M KH2PO4 in D2O, 0.1 % 3-(tri-
methylsilyl)-propionate acid-d4 (TSP), 3 mM NaN3). Next,
to get an overview of lipophilic substances, the following
sample preparation was used: 100 μL of a sample was
mixed with 800 μL CDCl3 containing 0.1% tetramethyl-
silane (TMS). After filtration (when necessary), 600 μL
of the solution was poured into an NMR tube for direct
measurement in both cases.
Stock standard solutions were prepared at a final con-
centration of about 10,000 mg/L in distilled water
(nicotine bitartrate, propylene glycol, 1,3-butanediol,
1,3-propanediol, ethylene glycol, diethylene glycol and
glycerol) or in deuterated chloroform (menthol, ethyl
vanillin, coumarin, camphor, safrole and α-thujone).
Calibration solutions were prepared by diluting the
standard solutions in water or in deuterated chloroform
and were measured as the authentic samples. The cali-
bration curves were evaluated by integrating specific
resonances of the selected compounds against TSP (in
water) or TMS (in CDCl3) as an intensity reference.
All NMR measurements were performed on a Bruker
Avance 400 Ultrashield spectrometer (Bruker Biospin,
Rheinstetten, Germany) equipped with a 5-mm SEI
probe with Z-gradient coils, using a Bruker Automatic
Sample Changer (B-ACS 120). All spectra were acquired
at 300.0 K.
NMR spectra of the aqueous solutions were acquired
using Bruker standard water suppression 1D noesygppr1d
pulse sequence with 64 scans (NS) and 4 prior dummy
scans (DS). The sweep width (SW) was 19.9914 ppm and
the time domain of the FID was 65536 (65 k). For the
spectra acquisition of chloroform-dissolved samples, the
Bruker experiment zg30 was used. After application of 2
dummy scans (DS), 8 free induction decays (FIDs) (NS =
128) were collected into a time domain of 131072 (131 k)
complex data points using a 20.5503 ppm spectral width
(SW) and a receiver gain (RG) of 101.
The data were acquired automatically under the
control of ICON-NMR (Bruker Biospin, Rheinstetten,
Germany), requiring about 40 min per sample for two
measurements. All NMR spectra were phased and
baseline-corrected.
The spectra of samples were compared to the spectra
of the standards. Separated peaks corresponding to each
substance were identified and integrated against TSP/
TMS as an intensity reference using TopSpin v. 3.1 (Bruker
Biospin, Rheinstetten, Germany). NMR ranges used for
identification/integration for all compounds are listed
in Table 1. Furthermore, all samples were screened for arange of small molecular weight molecules such as for-
maldehyde, acetaldehyde and acrolein.
We conducted a detailed validation for the determin-
ation of nicotine in e-cigarette liquids. For this substance
the limits of detection (LOD) and quantification (LOQ)
were calculated from the residual standard deviation of
the regression line [25]. To assess reproducibility, stand-
ard solutions as well as an e-cigarette liquid sample were
analyzed several times daily (n = 5). The recovery rate
was ascertained by adding nicotine standard solution at
four different concentrations to a real sample.
For other substances, the LOD and LOQ values were
determined as signals for which the signal-to-noise ratios
(SNR) are 3 and 10, correspondingly. SNR were cal-
culated using the Bruker sino routine implemented in
the Topspin 3.1 software package (Bruker Biospin,
Rheinstetten, Germany). The limits of the noise and sig-
nal regions were located near to each other and were set
manually for each spectrum.
The linearity of the calibration curves was evaluated in
the range covering the concentrations found in the in-
vestigated products.
Risk assessment
The methodology for comparative quantitative risk as-
sessment was based on a previous study conducted for
compounds in alcoholic beverages [26] with the excep-
tion that probabilistic exposure estimation was con-
ducted [27-29].
The toxicological thresholds, preferably benchmark
doses (BMD) or if unavailable no observed effect levels
(NOEL), no observed adverse effect levels (NOAEL) or
lowest observed adverse effect levels (LOAEL), for the
selected substances were typically identified in mono-
graphs of national and international risk assessment
bodies such as EFSA, OECD SIDS, JECFA, and ATSDR
[30-35], and if unavailable – as in the case of thujone -
taken from an own study [36].
The MOE approach was used for risk assessment
[37,38]. The MOE is defined as the ratio between the
lower one-sided confidence limit of the BMD (BMDL)
or NOEL/NOAEL/LOAEL and estimated human intake
of the same compound.
The exposure was estimated for daily users of e-
cigarettes based on the contents found in our chemical
analysis. Similar to the approach of Medeiros Vinci
et al. [39] for probabilistic human exposure assessment
of food contaminants, best fit distributions were ap-
plied to the substance contents and the resulting risk
functions were entered into the probabilistic analysis.
Further assumptions were literature data about typical
e-cigarette liquid use per day [40] and literature data
about vaporization percentage [19]. The bodyweight
was assessed as normal distribution with average of
Table 1 Selected resonances, limits of detection (LOD) and limits of quantification (LOQ) for compounds in e-cigarette
liquids
Substance Solvent NMR range used for integration [ppm] LOD [mg/L] LOQ [mg/L]
1 Nicotine Water 8.68-8.60 (multiplet) 1.6 5.5
2 Propylene glycol (1,2-propanediol) 3.47-3.42 (multiplet) 2.1 6.9
3 1,3-Butanediol 1.75-1.70 (multiplet) 2.3 7.6
4 1,3-Propanediol 1.85-1.75 (multiplet) 0.96 3.2
5 Ethylene glycol 3.69-3.67 (singlet) 0.17 0.56
6 Diethylene glycol 3.78-3.73 (multiplet) 0.51 1.7
7 Glycerol 3.82-3.75 (multiplet) 2.6 8.7
8 Menthol Chloroform 2.00-1.92 (multiplet) 12 40
9 Ethyl vanillin 9.81-9.83 (singlet) 1.0 3.4
10 Coumarin 7.80-7.65 (multiplet) 3.2 10
11 Camphor 2.40-2.30 (multiplet) 13 44
12 Safrole 6.80-6.60 (multiplet) 2.6 8.6
13 Thujone (sum of α- and β-diastereomers) 2.12-2.09 (singlet) 3.4 11
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males [41]. All risk functions were truncated at zero be-
cause negative values are factually impossible. Monte
Carlo simulations were performed with 10,000 iterations
using Latin Hypercube sampling and Mersenne Twister
random number generator. Calculations were performed
using the software package @Risk for Excel Version 5.5.0
(Palisade Corporation, Ithaca, NY, USA).
Results
NMR method development and validation results
Figure 1 shows the complete 1H NMR spectrum of a














Figure 1 1H NMR spectrum of the aqueous sample of a typical e-ciga
10–6 ppm region.liquid sample as well as a magnification of the δ 10–
6.0 ppm region, where the resonances of aromatic pro-
tons (for instance, from nicotine and ethyl vanillin) can
be observed. The mid-field region of NMR spectra con-
tains information about major solvents such as glycerol,
propylene glycol and ethylene glycol. NMR spectra of
chloroform-dissolved samples have the same principal
signals, however, some additional non-polar compounds
(e.g. thujone, camphor) can be seen.
The NMR ranges (i.e. peaks not overlapped or inter-
fered by matrix) selected for quantification are given in
Table 1. For example, nicotine, the principal compound
of interest in our research, has signals at δ 8.65 ppm4 2 0
6
ppm
rette liquid sample. The insert shows 1H NMR spectra in the
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4.32 ppm (s), δ 3.80 ppm (m), δ 3.30 ppm (m), δ
2.73 ppm (s), δ 2.68 ppm (m) and δ 2.38 ppm (m). How-
ever, the resonances in the aliphatic and mid-field ranges
were found unsuitable for quantification because they
showed strong overlap with other matrix compounds
(Figure 1). Considering the signals in the aromatic re-
gion, we decided to use the multiplet at δ 8.65 ppm for
quantification because this leads to the best sensitivity
and this signal was not interfered in any case. As an ex-
ample, Figure 2A shows the signal of nicotine in stand-
ard solutions and in four e-cigarette liquid samples
(from these, two products contained 19.0 mg/ml and
15.8 mg/ml nicotine and the other two contained not
detectable nicotine concentrations). For the other sub-
stances, signals not interfered by matrix were also iden-
tified (Table 1) and as example, spectra for glycerol,
propylene glycol and ethylene glycol in standard solu-
tions as well as in samples are presented in Figure 2B-D.
Table 2 summarizes the NMR method validation results
for nicotine. The 1H NMR assay was linear in a working
concentration range of 5–10,000 mg/L (R = 0.9992), which
means 0.050-100 mg/ml e-cigarette liquid considering
sample preparation. This range basically covers the levels
of nicotine in e-cigarette products and no further dilution/
extraction of the matrix is required. The LOD and LOQ
were 1.6 and 5.5 mg/L, correspondingly, which is equal to
0.016 and 0.055 mg/ml e-cigarette liquid. We propose to
consider our LOD value as a cut-off level, at which we can
distinguish nicotine-free and nicotine-containing products.
Furthermore, Table 1 contains LOD and LOQ values for
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Figure 2 NMR resonances of nicotine (A), glycerol (B), propylene glyc
liquid samplesvaried in the 0.17 - 13 mg/L range with the lowest values
for glycols (for ethylene glycol 0.17 mg/L and for diethyl-
ene glycol 0.51 mg/L) and highest for camphor (13 mg/L)
and menthol (12 mg/L) (Table 1). The LOQ values were
in the range between 1.7 mg/L (ethylene glycol) and
40 mg/L (menthol). The high correlation coefficients (R >
0.99) obtained for the calibration graphs indicate a good
linear response within the concentration range studied.
From fifty four samples investigated only in five we were
not able to directly quantify glycerol, ethylene glycol or
propylene glycol due to spectral overlap.
The method was further validated by repeated sample
preparation of a standard solution (1000 mg/L) and an
e-cigarette liquid sample (nicotine content 19.0 mg/ml).
Recoveries between 99% and 115% (average 107%) were
obtained when the standard addition method is applied
for an e-cigarette liquid sample. The variation coeffi-
cients were found to be 1.2% for the standard solution
and 2.1% for the product. In general, the results of the
method validation show that the method is sufficiently
precise and reproducible and is adequate for the purpose
of regulatory control of e-cigarette liquids (Table 1).
Moreover, reference HPLC analysis was performed for
a subgroup of 15 samples (Table 3). Statistical analysis
between results from the two methods (HPLC and
NMR) revealed that the linear correlation is significant
(ANOVA p < 0.0001, R = 0.98). No systematic or propor-
tional differences between both methodologies were
found, as the standard deviations of both the y-axis and
the slope were encompassing 0 or 1. The results con-
firmed the accuracy of our NMR method and its com-
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ol (C), ethylene glycol (D) in standard solutions and e-cigarette
Table 2 Results of method validation for nicotine
Parameter Result
Linear range 5-10,000 mg/L
(0.050- 100 mg/ml sample)
LODa 1.6 mg/L (0.0157 mg/ml
sample)
LOQa 5.5 mg/L (0.0546 mg/ml
sample)
Recovery 99% (at 1000 mg/L)
104% (at 1500 mg/L)
115% (at 1750 mg/L)








aLimit of detection (LOD) and quantitation (LOQ) were determined by
establishing a separate calibration curve near LOD (5.0-25 mg/L). The limits
were calculated from the residual standard deviation of the regression
line [25].
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the reference GC-MS values for a set of 10 samples. It
was found that the data of both methods are in good
agreement with each other: the relative difference varied
between 1.7% and 13% (average 8.1%) for 1,2-propane-
diol, between 2.8% and 7.3% (average 5.3%) for ethylene
glycol and between 0.45% and 12% (average 7.5%) for
glycerol.Table 3 Comparison of nicotine quantification results



















15 18.7 17.5Composition of e-cigarette liquids
The NMR methodology was used for analysis of 54 au-
thentic liquids for use in e-cigarettes. The results of
our investigations are summarized in Table 4. From the
analysed 54 samples, 34 (63%) contained nicotine above
the detection limit. The average and median concentra-
tions of nicotine in all investigated samples were 11
and 6.8 mg/ml, correspondingly (Table 4). In general,
the values were in agreement with labelling. However,
from 23 samples that were declared as nicotine-free,
only 18 were confirmed to contain undetectable nico-
tine concentrations by NMR. Nicotine was definitely
detected in 5 allegedly “nicotine-free” samples in a con-
centration range from 0.11 mg/ml to 6.9 mg/ml. In con-
trast, one e-cigarette liquid sample did not contain
nicotine, while its presence being declared on the label-
ling (12 mg/ml).
Glycerol and propylene glycol were detected in all
samples at concentrations ranging from 0.3 to 95 g/
100 g (average 37 g/100 g) for glycerol and from 0.4 to
98 g/100 g (average 57 g/100 g) for propylene glycol.
Generally, lower levels of another solvent ethylene glycol
(average 10 g/100 g) were detected. 1,3-Propanediol was
detected only in 7 samples in the concentration range of
3.3-10 g/100 g. 1,3-Butanediol, diethylene glycol, formal-
dehyde, acrolein, coumarin, camphor, safrole and men-
thol were negative in all samples.
The presence of the major compounds glycerol and
propylene glycol corresponded to the labelling in the
majority of cases, except 3 products contained no label-
ling information at all. Glycerol was not labelled on 5
products despite being present. Propylene glycol was
not labelled in 2 products despite being present. In one
case, “vegetal glycol” was labelled without specifying the
exact chemical compound. Ethylene glycol was not la-
belled on any of the samples, which did contain the
compound.
As for flavour compounds, which can be monitored
in NMR spectra of chloroform-dissolved samples, we
detected thujone (the sum of α-/β-diastereomers) in
two samples (183 and 178 mg/L) and ethyl vanillin
(concentration range 7.7-335 mg/L) in thirteen sam-
ples. We observed coumarin, camphor, safrole and
menthol in none of the samples (the presence of men-
thol was not labelled on any of the samples, however).
Interestingly, among other volatile aldehydic com-
pounds (acetaldehyde, formaldehyde and acrolein) we
observed only acetaldehyde in one sample at a concen-
tration of about 38 mg/L. Only 4 products contained a
detailed ingredients list with specific flavour com-
pounds pointed out. Most of the products labelled only
“flavour” or “natural and artificial flavours” without
pointing out specific substances, or completely lacked
any labelling.
Table 4 Overview about constituents in electronic cigarettes with descriptive statistics and best fit distributions
Agent Positive samples Mean Median Standard deviation Best fitting risk function for concentration of agent
in the beveragea
Nicotine (mg/ml) 65% 11 6.8 13 RiskNormal(11.023;13.134;RiskTruncate(0;))
Glycerol (g/100 g) 94% 37 35 23 RiskWeibull(1.8104;44.812;RiskShift(−2.8327);RiskTruncate(0;))
1,2-Propanediol (g/100 g) 94% 57 64 30 RiskTriang(−18.939;91.8;100.45;RiskTruncate(0;))
Ethylene glycol (g/100 g) 91% 10 5 18 RiskLoglogistic(−0.40204;5.15;1.8215;RiskTruncate(0;))
1,3-Propanediol (g/100 g) 13% 0.6 0 1.7 RiskResample(2;[all measurements])
Thujone (mg/L) 4% 6.7 0 34 RiskResample(2;[all measurements])
Ethyl vanillin (mg/L) 26% 30 0 68 RiskResample(2;[all measurements])
aThe best fit distributions were selected based on Kolmogorov-Smirnov statistics. For 1,3-propanediol, thujone and ethyl vanillin, distribution fitting was not
possible due to the low incidence. Random resampling is used for these agents from a data table with all measurements where all samples with not detectable
concentrations were treated as zero.
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Nicotine, glycerol, 1,2-propanediol, ethylene glycol, 1,3-
propanediol, thujone and ethyl vanillin were selected for
exposure assessment. An overview of the concentra-
tions of these compounds in e-cigarette liquids as well
as the best fitting risk functions that were selected as in-
put for probabilistic modelling are provided in Table 4.
The toxicological thresholds are shown in Table 5
[30-36,42-48]. To provide a conservative assessment,
the most sensitive toxicological endpoint was chosen,
when several endpoints were available. Only for nico-
tine, human data were available as basis for the assess-
ments. For the rest of the compounds, the assessments
have to be based on animal data. The thresholds of the
compounds vary over a very wide range, from 0.008 mg/
kg bodyweight(bw)/day for nicotine to 10,000 mg/kg
bw/day for glycerol.Table 5 Toxicological thresholds selected for calculating the m
Agent Toxicological Endpointa Value
bw/da
Nicotine Heart rate acceleration in humans 0.008
0.0008
Glycerol 2-year study in rats, no effects observed 10,000
1,2-Propanediol 2-year studies in rats and dogs, no effects observed
in rats, increased erythrocyte destruction in dogs
2,500
25
Ethylene glycol Developmental toxicity data in mice
(total malformations and a skeletal variation)
76
0.8
1,3-Propanediol Developmental toxicity study in rats 1,000
Thujone Clonic seizures in rats 11
0.11
Ethyl vanillin 13-week study in rats, no effects observed 500
3
aHuman data was preferred over animal data, if available. The most sensitive endpo
bBMDL10: lower one-sided confidence limit of the benchmark dose (BMD) for a 10%
Effect Level (NOAEL) are used in cases when no usable BMD-modelling for oral exp
risk level.
cThe lowest observed adverse effect level (LOAEL) is considered by EFSA [30] as clo
injected nicotine intravenously assuming an oral bioavailability of 44%.Table 6 presents the probabilistic exposure estimates.
In all cases, the highest exposure was detected for 1,2-
propanediol (average 14.5 mg/kg bw/day), while the
lowest was found for thujone (average 1.6E-04 mg/kg
bw/day).
The analysis also includes a sensitivity analysis, which
allows a ranking of the input distributions which impact
the exposure. In all cases, the concentration of the com-
pound in the liquid had the highest influence, followed
by vaporization percentage, e-cigarette liquid amount
per day and a minor influence of bodyweight (regression
coefficients for concentration ranging between 0.58 and
0.87, for vaporization percentage between 0.08 and 0.50,
for e-cigarette liquid amount per day between 0.04 and
0.43 and for bodyweight between −0.02 and −0.17).
Finally, the margins of exposure (MOE) for all com-






LOAELc EFSA [30] based on Lindgren et al. [42]
ADI
NOAEL OECD SIDS [31] based on Hine et al. [43]
NOAEL JECFA [32] based on Gaunt et al. [44]
and Weil et al. [45]
ADI
BMDL10 ATSDR [33] based on Neeper-Bradley et al.
[46] and Tyl et al. [47]
MRL
NOAEL EFSA Panel on Contaminants in the Food
Chain [34] based on unpublished data
BMDL10 Lachenmeier and Uebelacker [36] based
on NTP [48]
ADI
NOEL JECFA [35] based on unpublished data
ADI
int was chosen if dose–response data for several organ sites were available.
incidence of health effect. The No Effect Level (NOEL) or No Observed Adverse
osure was identified in the literature. ADI: acceptable daily intake. MRL: minimal
se to the NOAEL. The values were derived from a study in humans who were
Table 6 Estimated exposure (mg/kg bw/day) of electronic
cigarette users using Monte Carlo analysis (10,000
iterations)a
Agent Mean SD Median P5 P95
Nicotine 0.38 0.39 0.25 0.02 1.15
Glycerol 9.0 8.9 6.2 0.6 27.2
1,2-Propanediol 14.5 12.4 11.0 1.3 39.3
Ethylene glycol 2.1 6.7 0.9 0.1 7.1
1,3-Propanediol 0.14 0.51 0 0 1.1
Thujone 1.6E-4 9.7E-4 0 0 Max 0.01
Ethyl vanillin 7.2E-4 2.0E-3 0 0 Max. 0.03
aCalculated for all agents using the following formula with the risk functions
defined in Table 4:
Exposure = Risk function of concentration * Risk function of e-cigarette liquid
amount per day * Risk function of vaporization percentage / Risk function of
bodyweight (kg).
The risk function of e-cigarette liquid amount per day was RiskNormalAlt
(25%;3;75%;5;RiskTruncate(0;)) based on values from Farsalinos et al. [40]
The risk function of vaporization percentage was RiskUniform(6;81) based on
values from Goniewicz et al. [19].
The risk function of bodyweight was RiskNormal(73.9;12) according to average
and standard deviation from EFSA Scientific Committee [41].
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a MOE of 10, and on average below 0.1. From all other
compounds, only ethylene glycol may reach MOEs
below 100 in about 50% of cases and 1,2-propanediol in
worst cases (above the 75th percentile).
Discussion
Chemical analysis of e-cigarette liquids
Regarding nicotine quantification in e-cigarette liquids,




























































Figure 3 Margin of Exposure (MOE) for compounds occurring
in electronic cigarettes based on probabilistic exposure
estimation (simulation with 10,000 iterations). (The box is
determined by the 25th and 75th percentiles. The whiskers are
determined by the 5th and 95th percentiles. 1st and 99th percentiles
are marked by x, while minimum and maximum are marked with
dash. Values above 1E7 are not shown).HPLC-UV [12,13,17,49], headspace GC-MS [12], GC-FID
[50], and GC-TID (Thermionic specific detector) [19]. As
expected, our NMR method with a limit of detection
(LOD) of 1.6 mg/L is not as sensitive as these methods
(for example, the LOD of HPLC was about 0.1 mg/L [13]),
however it is sufficient to control the nicotine content in
nicotine-containing e-cigarette liquids (Table 1).
For the identification of the major ingredients (glycols
and glycerol) and their relative concentrations, gas chro-
matography with flame ionization detector (GC-FID) or
with mass spectrometry (MS) is usually used [50,51].
These methods provide adequate sensitivity, but have
the disadvantage of being very laborious and time-
consuming. Moreover, some authors noted a significant
matrix effect, which results in peak suppression of ana-
lytes [10,14]. This matrix effect effectively limits the
amount of propylene glycol and glycerol in the measure-
ment solution and necessitates dilution of the samples
with subsequent rise in LOD. For NMR, we found that a
dilution factor of 10 is sufficient to obtain good phase-
and baseline corrected spectra, which still provides suffi-
cient sensitivity for all compounds in e-cigarette liquids.
Thus, our results have shown that NMR is a good alter-
native for the control of nicotine and a number of other
compounds in e-cigarette liquids and it avoids the use of
two separate analytical techniques (HPLC for nicotine
and GC for volatiles).
1H-NMR spectroscopy can therefore provide quantita-
tive information necessary to judge about the compos-
ition of e-cigarette products in a short analysis period
(about 20 minutes including sample preparation). First and
foremost, we can provide very fast binary categorization, if
an e-cigarette liquid sample contains nicotine or not (LOQ
is about 0.050 mg/ml e-cigarette liquid) and, therefore,
control the labelling. This is not only required for mar-
ket control of the products but also important for con-
sumer health protection as an e-cigarette user could be
exposed to the hazard of nicotine dependence by pur-
chasing a product, which while advertised as containing
no nicotine does contain it. Moreover, all major com-
pounds could be identified and quantified using the same
spectral data. In case of spectral overlap, multivariate de-
convolution methods can be supplementarily used [52].
Similar to our findings, other authors have also
observed that the nicotine content of some e-cigarette
liquids is often inconsistent with the labelling [13,15].
Acetaldehyde, which we found in one sample, has been
also recently detected in one e-cigarette liquid sample by
Selected Ion Flow Tube Mass Spectrometry (SIFT-MS)
[10]. However, we think that it is currently not possible
to estimate acetaldehyde exposure by e-cigarette con-
sumption based on these single observations.
In our study we detected none of the tobacco-specific
impurities and tobacco specific nitrosamines by NMR
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ally found in trace concentrations, the sensitivity of NMR
is not sufficient to control the typical levels of these com-
pounds in e-cigarette liquids [10]. For the analysis of
tobacco-specific impurities and tobacco specific nitrosa-
mines, hyphenated methods such as HPLC-MS/MS, GC-
MS, headspace GC-MS or GC-MS/MS methods have to
be used [10,12,14,16,49]. Even applying these methods,
concentrations were usually found to be below LOQ levels
[10,12]. Tobacco-specific toxicants and trace nicotine im-
purities were judged as being below levels likely to cause
harm [17,20].
For our risk assessment, we have therefore focused on
the constituents with major occurrence in e-cigarette
liquids (nicotine, glycerol, 1,2-propanediol, and ethylene
glycol). 1,3-Propanediol, thujone and ethyl vanillin were
included as compounds of minor occurrence, but which
could be relevant for consumers that prefer single
brands of products in light of a worst-case scenario.
The risk of compounds in e-cigarette liquids
Exposure estimates may have considerable uncertainty
especially in the case of non-normal distributions, as in
our case of constituents in e-cigarette liquid. For this
reason, we decided to apply a probabilistic method,
which takes account of every possible value that each
variable can take and weight each possible scenario by
the probability of its occurrence [53]. To facilitate this,
we use the Monte-Carlo approach, which has been pre-
viously applied in food science to model dietary expos-
ure to chemicals in food [39,53,54], but this study is the
first to apply it to estimate the exposure to chemicals in
tobacco related products. The advantage of the approach
is that rather than single values for each scenario it gen-
erates distributions of the MOE, which allow a direct
visualization and comparison of all scenarios (Figure 3).
In line of a worst case scenario, we assume that the va-
porized percentage of the liquid may have a 100% bio-
availability either orally or inhalatory. As toxicological
thresholds for inhalation exposure were unavailable, we
use thresholds for oral exposure, which may be seen as a
limitation of the approach.
According to the typical interpretation of MOEs de-
rived from animal experiments (i.e. for all our com-
pounds except nicotine), MOE < 10 is judged to pose
“high risk”, while MOE < 100 are judged as “risk”. MOEs
above 100 are often judged as acceptable because the
value of 100 corresponds to the default 100-fold uncer-
tainty factor, which has been historically used in regula-
tory toxicology. The factor of 100 is based on scientific
judgement and represents the product of two separate
10-fold factors that allow for interspecies differences and
human variability [38,55]. When the toxicological end-
point is based on human data on not on animalexperiments as for nicotine, MOEs above 10 would be
judged acceptable and MOEs below 1 as “high risk”.
Using this interpretation of MOE, our evaluation clearly
shows that nicotine is by far the compound with the
highest risk in e-cigarette liquids. The MOE values of
nicotine are all below 10 and may reach down to below
0.1, which is the lowest level of all compounds under
study (Figure 3). Nicotine exposure would also exceed the
ADI as proposed by EFSA [30] for nicotine residues in
food products. Both 1,2-propanediol and ethylene glycol
may reach MOEs below 100 in some scenarios, which
may be interpreted as falling into the “risk” category.
Daily users of conventional cigarettes may have ac-
quired a very high tolerance to nicotine, so that our as-
sessment may overestimate the risk of this user group.
An overestimation of the risk of nicotine may also occur
by the endpoint of heart rate acceleration, which was se-
lected by EFSA in their risk assessment of nicotine in
foods [30]. It may be questioned if heart rate acceler-
ation is a suitable (adverse) endpoint for risk assessment.
The acute risk of nicotine may have been generally over-
stated in the past [56]. On the other hand, the chronic
risk of nicotine may not be adequately considered by the
endpoint chosen by EFSA [30] as well. For example,
some new in vitro evidence points to possible direct
carcinogenic and genotoxic effects of nicotine [57-60].
Nevertheless, epidemiological evidence for such an effect
of nicotine appears to be unavailable so far; and while
being on the “high priority” list for evaluation by the
WHO International Agency for Research on Cancer,
nicotine has so far not been classified by the agency.
In consideration of the potential over- or underestima-
tion of the effects of nicotine, we agree with EFSA [30]
to apply the heart-rate acceleration as most sensitive hu-
man endpoint till better data become available. Our risk
assessment provides evidence that non-tolerant users of
e-cigarettes should be clearly warned against using
liquids with higher nicotine contents. It should also be
noted as limitation that the potential hazard of nicotine
dependence, which may depend on the form and speed
of nicotine delivery [61], currently cannot be considered
due to lack of adequate dose–response data.
Average ethylene glycol exposure would also exceed
the minimal risk level of ATSDR [33]. It should be also
noted that ethylene glycol (in contrast to propylene gly-
col) is not included on the U.S. Food and Drug Adminis-
tration list of compounds “generally recognized as safe”
(GRAS) [62].
Nevertheless, we think that compared to nicotine, the
risks of 1,2-propanediol and ethylene glycol appear to be
minor. However, the difference is that nicotine is
intentionally ingested while the consumers certainly be-
lieves that all other constituents of the liquids are with-
out risk (especially considering the advertisement of e-
Hahn et al. Tobacco Induced Diseases  (2014) 12:23 Page 10 of 12cigarettes as risk-free alternatives to tobacco cigarettes).
For this reason in a conservative assessment, prudent
risk management could be to avoid or reduce these
compounds in the liquids and switch the formulations to
other solvents with more favourable toxicological pro-
files. The risk of the flavour compounds thujone and
ethyl vanillin appears to be rather low (MOE >1000) and
mitigation measures for toxicological reasons appear to
be not required.
Conclusions
E-cigarettes are a class of products that has emerged to
the mass market during the last decade and the regula-
tory status of which has been unclear in a borderline
area between regulations for medicinal products, to-
bacco products or general product safety rules.
One possibility would have been to regulate e-cigarettes
as medicinal product. Our research clearly shows that the
exposure of nicotine may reach amounts that facilitate a
pharmacological action in the user of the product in the
sense of the European medicines directive [63]. However,
there was a political decision against this option. Such
products will be regulated in the context of a revised to-
bacco products directive in the European Union, which
was formally approved by the European Parliament on 26
February 2014. The maximum nicotine threshold will be
20 mg/ml [64].
We fully agree with the intention of the regulation to
ensure uniform within-device dosing (i.e. the same prod-
uct should always be consistent in nicotine delivery,
which may be achieved by quality control of the liquids
as well as by ensuring consistent nicotine delivery from
the e-cigarette device) [65]. Our study has shown that
deviations from the labelling in certain products would
demand quality control procedures by official authorities
similar to other consumer products such as alcohol and
tobacco cigarettes. Liquids with high nicotine levels may
pose risks especially for non-tolerant users (i.e. users that
have not smoked before). Furthermore, the vaporization
percentage of the device has an important influence on
the exposure, so that the dosing in the device itself must
be controlled for consistency.
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